

Date: 02/05/2025

To
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai – 400 001

Manager - Listing
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 051

Ref: Script Code: 533259 and Symbol: SASTASUNDR
Sub: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Intimation of reduction of share capital of Genu Path Labs Limited, step-down subsidiary of the Company

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") read with para A of part A of Schedule III of the SEBI LODR Regulations, the Company has received intimation from Genu Path Labs Limited (GPL), step-down subsidiary of the Company and wholly owned subsidiary of Sastasundar Healthbuddy Limited that GPL has filed the scheme of reduction of share capital with the National Company Law Tribunal, Kolkata Bench in accordance with Section 66 read with Section 52 of the Companies Act, 2013; and National Company Law Tribunal (Procedure for reduction of Share Capital of Company) Rules, 2016 and other applicable provisions of the Act.

This scheme of reduction of share capital is subject to the approval and confirmation by the National Company Law Tribunal and the said Scheme does not affect the management or control of the Company in any manner.

The details as required under SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are given in Annexure-A to this letter.

The Company has received an intimation on May 2, 2025 at 7:32 P.M. that the GPL has filed the scheme of reduction of share capital with the National Company Law Tribunal for their approval.

This is for your information and records.

Yours Faithfully,
For Sastasundar Ventures Limited

Pratap Singh
Company Secretary and Compliance Officer
Encl: A/a



ANNEXURE-A

The disclosure in respect of the aforesaid Scheme of Reduction of Capital of Genu Path Labs Limited, step-down subsidiary as required under Para A of Part A of Schedule III of Regulation 30 of the SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023:

Sr. No	Details of Events that need to be provided	Information of such events(s)
A	Details and reasons for restructuring	<p>Genu Path Labs Limited (GPL) has Paid up Share Capital of Rs. 19,74,99,980/- which consists of 1,97,49,998 number of equity shares of Rs. 10/- each. GPL has accumulated loss at INR (3892.75) lacs as on 31st December, 2024.</p> <p>For ensuring that the financial statements of GPL reflect the true and fair value and align the balance sheet with the present operational realities it is necessary to carry out reduction of capital of GPL.</p>
B	Quantitative and/or qualitative effect of restructuring	<p>Upon the Scheme becoming effective, the Existing Paid-Up Equity Share Capital from Rs. 19,74,99,980 divided into 1,97,49,998 equity shares of Rs. 10 each each shall be reduced to Rs. 1,97,49,998 divided into 1,97,49,998 Equity Shares of Re. 1/- each, by cancelling and extinguishing, in aggregate, 90% of the total issued, subscribed and paid-up equity share capital of GPL, comprising 17,77,49,982 Equity Shares of Rs. 10/- each, held by the members of GPL and write off Accumulated losses to the extent of the entire balance appearing in the Securities Premium Account.</p> <p>The Scheme, if approved, may improve the Networth of Genu Path Labs Limited.</p>
C	Details of benefit, if any, to the promoter/ promoter group/ group companies from such proposed restructuring	The Scheme of Reduction of Capital does not result in any benefits to the Promoter /Promoter Group/ Group Companies because there is no Change in percentage (%) of their shareholding.
D	Brief details of change in shareholding pattern (if any) of all entities	No Change

